Apolipoprotein A-I improves hepatic autophagy through the AMPK pathway

Area of Science:

• Biochemistry
• Cell Biology
• Metabolic Diseases

Background:

• Lipid metabolism dysfunction is linked to reduced hepatic autophagy and non-alcoholic steatohepatitis (NASH).
• ATP-binding cassette transporter A1 (ABCA1) facilitates cholesterol and phospholipid transport to apolipoprotein A-I (apoA-I), forming high-density lipoprotein particles.
• Previous studies indicated apoA-I overexpression reduces hepatic lipids and endoplasmic reticulum stress by altering lipid transport.

Purpose of the Study:

• To investigate the impact of apoA-I overexpression on hepatic autophagy in cultured hepatocytes and mice.
• To elucidate the molecular mechanisms underlying apoA-I's effects on autophagy.

Main Methods:

• Overexpression of apoA-I in HepG2 cells and apoA-I transgenic mice.
• Assessment of autophagy levels, including phosphorylation of AMP-activated protein kinase α (AMPKα), ULK1, and mammalian target of rapamycin (mTOR).
• Utilized an AMPK inhibitor and small interfering RNA (siRNA) to block AMPK signaling.

Main Results:

• ApoA-I overexpression in HepG2 cells increased autophagy, AMPKα and ULK1 phosphorylation, and decreased mTOR phosphorylation.
• Inhibition of AMPK or ULK1 using siRNA abolished the effects of apoA-I.
• ApoA-I transgenic mice exhibited elevated autophagy and AMPKα phosphorylation.

Conclusions:

• ApoA-I overexpression enhances hepatic autophagy through the AMPK-mTOR-ULK1 signaling pathway.
• This mechanism suggests apoA-I as a potential therapeutic target for alleviating steatohepatitis.